Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Invested Capital (2016 - 2025)

Fennec Pharmaceuticals' Invested Capital history spans 15 years, with the latest figure at $35.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 187.6% year-over-year to $35.5 million, compared with a TTM value of $35.5 million through Dec 2025, up 187.6%, and an annual FY2025 reading of $35.5 million, up 187.6% over the prior year.
  • Invested Capital for Q4 2025 was $35.5 million at Fennec Pharmaceuticals, up from $13.7 million in the prior quarter.
  • The five-year high for Invested Capital was $35.5 million in Q4 2025, with the low at $2.8 million in Q3 2022.
  • Average Invested Capital over 5 years is $19.0 million, with a median of $17.7 million recorded in 2023.
  • Year-over-year, Invested Capital crashed 88.33% in 2022 and then soared 416.38% in 2023.
  • Tracing FENC's Invested Capital over 5 years: stood at $24.0 million in 2021, then decreased by 6.59% to $22.4 million in 2022, then dropped by 18.07% to $18.4 million in 2023, then crashed by 32.89% to $12.3 million in 2024, then soared by 187.6% to $35.5 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Invested Capital are $35.5 million (Q4 2025), $13.7 million (Q3 2025), and $10.7 million (Q2 2025).